Lantheus Holdings (NASDAQ: LNTH) held its fourth-quarter and full-year 2024 earnings call on Feb. 26, 2025, highlighting achievements in its radiopharmaceutical portfolio and announcing strategic ...

Q4 2024 Earnings Call Transcript February 26, 2025 Operator: Good morning. Welcome to the Lantheus Fourth Quarter and Full Year 2024 Conference Call. [Operator Instructions]. This call is being ...

Worldwide revenue of $391.1 million and $1.53 billion for the fourth quarter and full year 2024Free cash flow was $141.4 million and $493.1 ...

Welcome to the Lantheus fourth quarter and full year 2024 conference call. (Operator Instructions) This call is being recorded, and a replay will be available in the Investors section of the company's ...

Welcome to the Lantheus Fourth Quarter and Full Year 2024 Conference Call. [Operator Instructions]. This call is being recorded and a replay will be available in the Investors section of the company's ...

today announced a definitive agreement to acquire Evergreen Theragnostics, Inc. ("Evergreen"), in an all-cash transaction consisting of an upfront payment of $250 million and up to an additional $ ...

Reports Q4 revenue $391.1M, consensus $376.18M. “2024 was a groundbreaking year for Lantheus (LNTH), as our radiodiagnostic, PYLARIFY, reached ...

Now the UK pharma is aiming to build on this by striking a licence arrangement with UK biotech Theragnostics to develop based on poly (ADP-ribose) polymerase (PARP) inhibitors attached to a ...

Berlin-headquartered Ariceum, which launched in 2021, had earlier acquired Theragnostics Ltd in June 2023, which undertook initial development work on I-ATT001. Dermavant announces new positive ...

After hours: 21 February at 5:57:19 pm GMT-5 ...